These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 7911760

  • 21. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
    Rogers BE, McLean SF, Kirkman RL, Della Manna D, Bright SJ, Olsen CC, Myracle AD, Mayo MS, Curiel DT, Buchsbaum DJ.
    Clin Cancer Res; 1999 Feb; 5(2):383-93. PubMed ID: 10037188
    [Abstract] [Full Text] [Related]

  • 22. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ.
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.
    Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R.
    Eur J Nucl Med; 2000 Sep; 27(9):1318-25. PubMed ID: 11007513
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
    Akizawa H, Arano Y, Uezono T, Ono M, Fujioka Y, Uehara T, Yokoyama A, Akaji K, Kiso Y, Koizumi M, Saji H.
    Bioconjug Chem; 1998 Sep; 9(6):662-70. PubMed ID: 9815158
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M, Bakker WH, Breeman WA, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt M, Béhé M, Mäcke HR, Krenning EP.
    Int J Cancer; 1998 Jan 30; 75(3):406-11. PubMed ID: 9455802
    [Abstract] [Full Text] [Related]

  • 31. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.
    Clin Endocrinol (Oxf); 1998 Mar 30; 48(3):303-9. PubMed ID: 9578820
    [Abstract] [Full Text] [Related]

  • 32. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P.
    Breeman WA, VanHagen MP, Visser-Wisselaar HA, van der Pluijm ME, Koper JW, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Hazenberg MP, Lamberts SW, Visser TJ, Krenning EP.
    J Nucl Med; 1996 Jan 30; 37(1):108-17. PubMed ID: 8543978
    [Abstract] [Full Text] [Related]

  • 33. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, McIlrath EM.
    QJM; 1998 Apr 30; 91(4):295-301. PubMed ID: 9666953
    [Abstract] [Full Text] [Related]

  • 34. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
    Haldemann AR, Rösler H, Barth A, Waser B, Geiger L, Godoy N, Markwalder RV, Seiler RW, Sulzer M, Reubi JC.
    J Nucl Med; 1995 Mar 30; 36(3):403-10. PubMed ID: 7884502
    [Abstract] [Full Text] [Related]

  • 35. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A.
    J Nucl Med; 2000 Sep 30; 41(9):1514-8. PubMed ID: 10994731
    [Abstract] [Full Text] [Related]

  • 36. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, Neuhold N, Kaserer K, Leimer M, Peck-Radosavljevic M, Scheithauer W, Niederle B, Eichler HG, Valent P.
    Eur J Nucl Med; 1996 Oct 30; 23(10):1388-99. PubMed ID: 8781146
    [Abstract] [Full Text] [Related]

  • 37. Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector.
    Benjegård SA, Forssell-Aronsson E, Wängberg B, Skånberg J, Nilsson O, Ahlman H.
    Eur J Nucl Med; 2001 Oct 30; 28(10):1456-62. PubMed ID: 11685487
    [Abstract] [Full Text] [Related]

  • 38. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E, Bomanji J, Mather SJ, Britton KE, Wass JA, Grossman AB, Besser GM.
    Clin Endocrinol (Oxf); 1993 May 30; 38(5):501-6. PubMed ID: 8101146
    [Abstract] [Full Text] [Related]

  • 39. 111In-octreotide scintigraphy in oncology.
    Krenning EP, Kwekkeboom DJ, Reubi JC, van Hagen PM, van Eijck CH, Oei HY, Lamberts SW.
    Digestion; 1993 May 30; 54 Suppl 1():84-7. PubMed ID: 8359573
    [Abstract] [Full Text] [Related]

  • 40. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
    Nilsson S, Reubi JC, Kalkner KM, Laissue JA, Horisberger U, Olerud C, Westlin JE.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.